Moderna and Merck shares tumble as unverified melanoma vaccine details surface on X ahead of trial data presentation
Moderna and Merck are conducting a collaborative study of a personalized mRNA melanoma vaccine given together with Keytruda after surgery. The vaccine is designed to match each tumor's unique genetic mutations. Results are slated for presentation at the European Society for Medical Oncology conference and have been approved for publication in the New England Journal of Medicine.
Shares of both companies fell after unverified information appeared on X, mentioning the vaccine name intismeran autogene and a claimed 42% reduction in recurrence or mortality. The episode highlights how rumors can quickly affect biotech stock valuations.
How this was covered
- Right-leaning outlets covered this 5h later
Why it matters
The story shows how speculative leaks can sway investor confidence in high‑profile cancer therapies.
How this story developed
- Oct 22 Moderna and Merck shares tumble after unverified vaccine details surface on X
- Oct 23 Shares of Moderna and Merck fell sharply after unverified vaccine details were posted on X.
- Oct 24 Results are slated for presentation at the ESMO conference and have been approved for publication in NEJM.
Related stories
5 in this thread